Receive The Newest Study Notifications

MRI-guided imaging helps team identify amyloid buildup that is then targeted with focused ultrasound Vibhor Krishna, M.D., (right) fits David Shorr with a helmet-like device used in a new clinical trial for Alzheimer’s disease at The Ohio State University Wexner...

Cohort two fully enrolled in a wide range of cancer types  Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today...

Neuropore Therapies, Inc. announced today that it has initiated a Phase 1 clinical trial in healthy volunteers with NPT520-34. This Phase 1 study is designed to evaluate the safety, tolerability and pharmacokinetics of NPT520-34. NPT520-34 is an orally bioavailable,...

ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced initiation of...

Increasing visibility of potential study participants to sites and sponsors -ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced...

Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the dosing of a first patient in a Phase 2a clinical study for the company’s HepaStem development program in patients with late stage non-alcoholic...

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced preliminary top-line results from its Phase 1b PULSE study which evaluated PRV-300, an anti-TLR3...

- No dose-limiting toxicities or safety concerns observed in first cohort of treated patients - Feasibility of streamlined, faster CAR therapy manufacturing process confirmed - Dosing initiated in second cohort of patients MaxCyte, the global clinical-stage cell-based...

SL-279252 is the first Agonist Redirected Checkpoint molecule to enter clinical development from the Shattuck pipeline. Shattuck Labs, Inc. (“Shattuck”), a biopharmaceutical company, announced today that patients are being treated in its Phase 1 dose escalation and...

Fast Track and Orphan Drug Status; No treatment currently exists for advanced liver cancer patients in whom the current standard of care does not work Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary...

Topline results now anticipated in 2H 2019 Trial enriched with only patients with history of inadequate response to prior migraine treatments Trial compares AXS-07 to placebo and active comparator Trial being conducted under FDA Special Protocol Assessment (SPA)...

Multinational Research Collaboration Advances Apabetalone Towards Phase 2 Clinical Trial for PAH Patients Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Multicenter Preclinical Validation of...

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, and Almac Diagnostic Services, a global stratified medicine company, today announced approval by the U.S. Food and Drug Administration...

  VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a contract under the previously announced Memorandum of Understanding, to conduct its first large-scale lung...

Randomized controlled study is first to demonstrate treatment efficacy using mobile devices for self-management of low back pain Kaia Health, a digital therapeutics company, announced results from the first randomized controlled trial of its app-based therapy program...

Positive Results Seen for Both Pain and Inflammation Mati Therapeutics Inc. (“Mati”) announced that it has completed a Phase II clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute®sustained ocular punctal plug drug...

 Vytronus, Inc., a privately held medical device company developing novel technologies for the treatment of cardiac arrhythmias, announced today that its early feasibility study of automated ultrasound technology for the treatment of persistent atrial fibrillation...

Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today a collaboration with University Medical Center Groningen (UMCG), Netherlands, to evaluate KidneyIntelX™ across over 3,500 patients...

Top-line Data Readout on Target for early Q4 2019 Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today...

GenSight Biologics (Paris: SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced...